Dianthus Therapeutics, Inc. (DNTH)
102.49
-2.28
(-2.18%)
USD |
NASDAQ |
Sep 16, 16:00
102.49
0.00 (0.00%)
After-Hours: 18:30
Dianthus Therapeutics Enterprise Value : 4.856B for Sept. 15, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 15, 2026 | 4.856B |
| September 14, 2026 | 5.016B |
| September 11, 2026 | 4.934B |
| September 10, 2026 | 4.774B |
| September 09, 2026 | 4.980B |
| September 08, 2026 | 5.095B |
| September 04, 2026 | 5.038B |
| September 03, 2026 | 5.024B |
| September 02, 2026 | 4.936B |
| September 01, 2026 | 4.957B |
| August 31, 2026 | 4.902B |
| August 28, 2026 | 4.914B |
| August 27, 2026 | 5.227B |
| August 26, 2026 | 5.184B |
| August 25, 2026 | 5.258B |
| August 24, 2026 | 5.146B |
| August 21, 2026 | 5.203B |
| August 20, 2026 | 5.115B |
| August 19, 2026 | 5.345B |
| August 18, 2026 | 5.446B |
| August 17, 2026 | 5.409B |
| August 14, 2026 | 5.469B |
| August 13, 2026 | 5.120B |
| August 12, 2026 | 5.274B |
| August 11, 2026 | 5.060B |
| Date | Value |
|---|---|
| August 10, 2026 | 5.241B |
| August 07, 2026 | 5.083B |
| August 06, 2026 | 5.138B |
| August 05, 2026 | 5.279B |
| August 04, 2026 | 5.164B |
| August 03, 2026 | 4.924B |
| July 31, 2026 | 4.974B |
| July 30, 2026 | 5.287B |
| July 29, 2026 | 4.818B |
| July 28, 2026 | 4.683B |
| July 27, 2026 | 4.840B |
| July 24, 2026 | 4.806B |
| July 23, 2026 | 4.857B |
| July 22, 2026 | 4.746B |
| July 21, 2026 | 4.908B |
| July 20, 2026 | 4.649B |
| July 17, 2026 | 4.901B |
| July 16, 2026 | 4.339B |
| July 15, 2026 | 4.589B |
| July 14, 2026 | 4.664B |
| July 13, 2026 | 4.520B |
| July 10, 2026 | 4.463B |
| July 09, 2026 | 4.596B |
| July 08, 2026 | 4.489B |
| July 07, 2026 | 4.362B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Verastem, Inc. | 612.11M |
| AbbVie, Inc. | 529.11B |
| TG Therapeutics, Inc. | 8.321B |
| Krystal Biotech, Inc. | 9.128B |
| Legend Biotech Corp. | 2.737B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -50.22M |
| Revenue (Quarterly) | 0.761M |
| Total Expenses (Quarterly) | 50.98M |
| EPS Diluted (Quarterly) | -0.8962 |
| Gross Profit Margin (Quarterly) | 85.94% |
| Profit Margin (Quarterly) | -6.60K% |
| Earnings Yield | -4.05% |
| Normalized Earnings Yield | -4.051 |